Lysogene, a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced that it has secured a €4.3 million non-dilutive financing...
CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, reported data from its trial treating...
Puma Biotechnology, Inc. a biopharmaceutical company, announced that the United States Patent and Trademark Office (USPTO) issued a Patent Term Extension Certificate for U.S....
Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced it entered into...
Red Cell Partners (“Red Cell”), an investment and incubation firm that backs, builds, and scales technology-led companies in healthcare and defense, today announced the...
